Swiss researchers may have discovered the reason drug-eluting stents cause thrombosis, and their study results are published today, Jan. 2, in the Journal of the American College of Cardiology.

The study suggests that the drugs with which stents are coated may stunt the heart’s natural ability to form new collateral blood vessels that can salvage heart muscle by rerouting the blood supply.

Implant Sciences Corp. a wholly-owned German subsidiary of CorNova, Inc., has received CE Mark marketing approval for its Valecor Coronary Stent System.

The cobalt-chromium stent is designed maximize flexibility and conformity while providing uniform expansion and coverage. Utilizing some of the thinnest struts of any commercialized coronary stent, the Valecor stent minimizes strut thickness, which is believed to play a significant role in reducing restenosis.

Reuters reports that a study of military veterans suffering from post-traumatic stress disorder showed that more severe their anxiety, the greater their risk of heart disease. Adding to the long-recognized connection between stress and heart disease, researchers at the Harvard School of Public Health in Boston said that relationship existed among nearly 2,000 Boston-area veterans.

Cardiac Science and School Health Corp. have announced an agreement under which School Health will sell and distribute Cardiac Science's Powerheart AEDs to schools and school districts in the U.S. They also said that the Texas Association of School Boards' (TASB) Risk Management Fund has purchased 292 Powerheart G3 Automatic AEDs and will provide them to a select group of school districts in Texas.

The latest in thrombus removal devices from Possis has received FDA clearance — the new AngioJet Ultra Thrombectomy System is the next-generation, re-engineered version of the company’s AngioJet Rheolytic Thrombectomy System.

The FDA has granted 510(k) marketing clearance for Atrium Medical Corp.’s ClearWay RX, a therapeutic perfusion catheter indicated for localized delivery of therapeutic agents to the coronary and peripheral vasculature.

A low-pressure perfusion catheter that incorporates a patented microporous PTFE balloon, Clearway RX enables controlled infusion at very low pressures (2 - 4atm) for maximum local therapeutic effect at a discrete targeted location. Delivering a smaller quantity of a preferred therapeutic agent locally has been shown to help reduce systemic effects.

The first patients to receive a new, implanted heart-monitoring device underwent procedures recently at the Clinica Marbella in Panama City, Panama.

The Sleuth Implantable ECG Monitoring System from Transoma Medical is a small medical device about the size of a 50-cent coin, was placed under the skin and continuously monitors the patient's heart.

Response Biomedical Corp. has filed an FDA 510(k) submission seeking clearance to market its RAMP NT-proBNP Test for the diagnosis of congestive heart failure. The Company has also completed a European CE Declaration to market the product in Europe.

UnitedHealthcare has announced its support for the “Door to Balloon (D2B): An Alliance for Quality” campaign recently initiated by the ACC and supported by 22 partnering organizations including the American Heart Association (AHA).

Viking Systems Inc., a designer of 3D and 2D high-performance surgical visualization systems, has launched the Viking Systems ViCam Vision System for monitoring, managing and recording complex open surgical procedures for cardiology.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now